PPMD is thrilled to announce our partnership with Duchenne UK to launch a joint 2020 Research Grant Call, inviting research proposals for submission and review. Up to $1 million (US) is committed to a project or projects seeking to minimize the immunological issues of gene therapy to treat Duchenne.
Like PPMD, our friends at Duchenne UK have a history of investing in innovative research, including gene therapy. By combining forces, PPMD and Duchenne UK are able to increase their global reach to attract the most promising new research.
PPMD’s Founding President & CEO, Pat Furlong, and Duchenne UK’s CEO, Emily Crossley explained in a joint statement:
“Supporting patients and accelerating innovative research is at the heart of what we do at Duchenne UK and PPMD. We are pleased to partner with each other and offer this grant of $1 million (US). Gene therapy is offering great promise, but there are challenges associated with the immune response which are limiting the rate of progress and a barrier to ensuring all patients can have access to these potentially transformative therapies. We hope that this call will encourage those working in this area to submit applications and engage with us in bringing new treatments to the clinic.”
By partnering together to identify and support these cutting-edge projects Duchenne UK and PPMD seek to accelerate the timeline of translation to patients in need of these exciting therapies.
What We’re Funding
PPMD and Duchenne UK hope to find projects through our Grant Call to advance the understanding of the best ways to safely, effectively, and repeatedly deliver gene therapies to the muscles where they are needed.
We invite proposals which are investigating ways to mitigate the immune response both in terms of pre-existing immunity and immunity induced by receiving a gene therapy dose. These may focus on ‘damping down’ or ‘circumventing’ the immune system itself or may be investigating alternative delivery methods that promote a minimal immune response.
Why We’re Funding It
Over the last few years, there has been huge progress in the treatment of the root cause of Duchenne through the delivery of replacement (‘micro’) dystrophin using gene therapy. Several gene therapy programs are now being tested in clinical trials on patients with Duchenne. Although it is still early stages, there is evidence that the presence of micro-dystrophin protein is detected in treated patients.
A common feature of all these gene therapy programs is their use of a virus to deliver the therapeutic material. Challenges can arise from an individual’s immune system preventing safe and successful delivery.
A significant number of patients have a natural immunity to the virus (and so are ineligible for treatment), but even those without immunity will develop it after the first administration, making second dosing (if required) very difficult.
To submit an application for consideration, please click here to learn more. All submissions will be carefully reviewed, initially by a joint Science Review team and by the CEOs from DUK and PPMD. Subsequently there will be a thorough review of proposals by a specially convened Scientific Advisory Board.
To learn more about PPMD’s innovative research agenda and our investment portfolio, visit PPMD’s website.